{"id":634532,"date":"2023-01-18T16:32:01","date_gmt":"2023-01-18T16:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634532"},"modified":"2023-01-18T16:32:01","modified_gmt":"2023-01-18T16:32:01","slug":"dengue-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dengue-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634532.html","title":{"rendered":"Dengue Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1674033465.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dengue Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1674033465.jpeg\" alt=\"Dengue Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Dengue Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cDengue Fever \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">United States, Nevada, Las Vegas, DelveInsight&rsquo;s <strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dengue-fever-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Dengue Pipeline Insight 2023<\/strong><\/a><strong>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Dengue therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dengue pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dengue-fever-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Dengue Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over 10+ Dengue pipeline therapies are in various stages of development, and their anticipated acceptance in the Dengue market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Dengue companies developing novel drug candidates to improve the Dengue treatment landscape include<strong> Takeda, Merck Sharp &amp; Dohme, AbViro LLC, <\/strong>and others.<\/li>\n<li>Promising Dengue pipeline therapies in various stages of development include <strong>TAK003, V180, AV1, <\/strong>and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Dengue Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Dengue Virus (DENV) is an arbovirus (arthropod-borne virus). Four serotypes of DENV are responsible for the infectious disease called dengue that annually affects nearly 400 million people worldwide. Dengue fever is a common mosquito-borne illness in many tropical and subtropical countries. Classic dengue fever, or &ldquo;break bone fever,&rdquo; is characterized by acute onset of high fever 3&ndash;14 days after the bite of an infected mosquito. Some patients with dengue fever go on to develop dengue hemorrhagic fever (DHF), a severe and sometimes fatal form of the disease. Millions of cases of dengue infection occur worldwide each year. Dengue fever is most common in Southeast Asia, the western Pacific islands, Latin America and Africa. Severe dengue fever happens when blood vessels become damaged and leaky. And the number of clot-forming cells (platelets) in bloodstream drops. This can lead to shock, internal bleeding, organ failure and even death.<\/p>\n<p style=\"text-align: justify;\"><strong>Dengue Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>AV1: AbViro LLC<\/strong><\/p>\n<p style=\"text-align: justify;\">AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact. Currently Av1 is being studied in phase I in adult healthy individuals.<\/p>\n<p style=\"text-align: justify;\">Discover more about the emerging Dengue drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dengue-fever-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Dengue Treatment Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Dengue Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Takeda<\/li>\n<li>Merck Sharp &amp; Dohme<\/li>\n<li>AbViro LLC<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Dengue Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>TAK003<\/li>\n<li>V180<\/li>\n<li>AV1<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Dengue Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By development stage<\/strong><\/li>\n<li><strong>By product type<\/strong><\/li>\n<li><strong>By route of administration<\/strong><\/li>\n<li><strong>By molecule type<\/strong><\/li>\n<li><strong>By MOA type&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Dengue Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Dengue Companies<\/strong>: Takeda, Merck Sharp &amp; Dohme, AbViro LLC, and others<\/li>\n<li><strong>Key Dengue Pipeline Therapies<\/strong>: TAK003, V180, AV1, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out more about the Dengue treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dengue-fever-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Dengue Clinical Trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample report to know more about the leading companies in the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dengue-fever-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">dengue fever pipeline domain<\/a>.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dengue-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dengue-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dengue Pipeline Insights DelveInsight\u2019s, \u201cDengue Fever \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dengue-clinical-trials-a-drug-pipeline-analysis-report-2023-delveinsight_634532.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-634532","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634532"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634532\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}